Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 60,720 shares of the biopharmaceutical company’s stock, valued at approximately $754,000. Los Angeles Capital Management & Equity Research Inc. owned 0.14% of Intra-Cellular Therapies as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of ITCI. Clough Capital Partners L P boosted its stake in Intra-Cellular Therapies by 157.0% during the first quarter. Clough Capital Partners L P now owns 898,750 shares of the biopharmaceutical company’s stock valued at $14,605,000 after buying an additional 549,100 shares during the period. Renaissance Technologies LLC bought a new stake in Intra-Cellular Therapies during the first quarter valued at $4,485,000. Vanguard Group Inc. boosted its stake in Intra-Cellular Therapies by 7.3% during the first quarter. Vanguard Group Inc. now owns 2,741,887 shares of the biopharmaceutical company’s stock valued at $44,556,000 after buying an additional 186,165 shares during the period. Federated Investors Inc. PA boosted its stake in Intra-Cellular Therapies by 113.3% during the second quarter. Federated Investors Inc. PA now owns 183,035 shares of the biopharmaceutical company’s stock valued at $2,273,000 after buying an additional 97,228 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Intra-Cellular Therapies by 192.2% during the first quarter. Dimensional Fund Advisors LP now owns 124,622 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 81,969 shares during the period. 71.79% of the stock is owned by institutional investors.

Shares of Intra-Cellular Therapies Inc. (NASDAQ ITCI) opened at 19.25 on Friday. The company’s market cap is $835.91 million. Intra-Cellular Therapies Inc. has a 52 week low of $7.85 and a 52 week high of $44.19. The firm’s 50-day moving average price is $15.29 and its 200 day moving average price is $13.12.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.33. Intra-Cellular Therapies had a negative net margin of 32,834.94% and a negative return on equity of 27.92%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.03 million. During the same period in the prior year, the business posted ($0.71) EPS. The business’s revenue for the quarter was down 52.2% compared to the same quarter last year. On average, equities research analysts forecast that Intra-Cellular Therapies Inc. will post ($2.36) EPS for the current year.

Several research firms recently issued reports on ITCI. Piper Jaffray Companies set a $10.00 price objective on Intra-Cellular Therapies and gave the company a “hold” rating in a research note on Thursday, August 10th. Cantor Fitzgerald reissued a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, August 9th. BidaskClub lowered Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Tuesday, August 15th. Finally, ValuEngine raised Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research note on Friday, August 18th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $27.11.

WARNING: “60,720 Shares in Intra-Cellular Therapies Inc. (ITCI) Acquired by Los Angeles Capital Management & Equity Research Inc.” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/22/60720-shares-in-intra-cellular-therapies-inc-itci-acquired-by-los-angeles-capital-management-equity-research-inc.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc. (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Stock Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related stocks with our FREE daily email newsletter.